Markers of muscarinic deficit for individualized treatment in schizophrenia.

Abstract

Recent clinical studies have shown that agonists at muscarinic acetylcholine receptors effectively reduce schizophrenia symptoms. It is thus conceivable that, for the first time, a second substance class of procholinergic antipsychotics could become established alongside the usual antidopaminergic antipsychotics. In addition, various basic science studies suggest that there may be a subgroup of schizophrenia in which hypofunction of muscarinic acetylcholine receptors is of etiological importance. This could represent a major opportunity for individualized treatment of schizophrenia if markers can be identified that predict response to procholinergic vs. antidopaminergic interventions. In this perspective, non-response to antidopaminergic antipsychotics, specific symptom patterns like visual hallucinations and strong disorganization, the presence of antimuscarinic antibodies, ERP markers such as mismatch negativity, and radiotracers are presented as possible in vivo markers of muscarinic deficit and thus potentially of response to procholinergic therapeutics. Finally, open questions and further research steps are outlined.

• Authors: Heiner Stuke
• Journal: Frontiers in psychiatry (Front Psychiatry) Vol. 13 Pg. 1100030 ( 2022) ISSN: 1664-0640 [Print] Switzerland
• PMID: 36699495 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Stuke.